Raltegravir Solid Composition With pH-Modulated Oral Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing raltegravir compositions exhibit poor aqueous solubility and absorption in the gastrointestinal tract, necessitating improved formulations to enhance solubility and bioavailability.
Innovation Solution
A solid pharmaceutical composition comprising raltegravir or its pharmaceutically acceptable salts, pH modifying agents, and excipients such as acidifying agents, superdisintegrants, binders, fillers, and lubricants, which modulate the microenvironmental pH and improve physicochemical and pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If raltegravir is formulated as a solid pharmaceutical composition, then oral administration is enabled, but aqueous solubility and absorption in the gastrointestinal tract remain poor
Solution Approach 1:
The patent applies pH modifying agents to change the microenvironmental pH parameters within the solid dosage form. This parameter change enhances the solubility and absorption of raltegravir in the gastrointestinal tract while maintaining the solid formulation for oral administration. The pH modification creates favorable conditions for drug dissolution and absorption without compromising the solid dosage form structure.
2Reliability
If pH modifying agents are added to enhance solubility and bioavailability, then drug absorption improves, but formulation complexity increases
Solution Approach 1:
The patent combines pH modifying agents with excipients and raltegravir into a unified solid pharmaceutical composition. This merging approach integrates the solubility-enhancing function of pH modifiers with the structural and functional requirements of the dosage form, achieving improved bioavailability without proportionally increasing formulation complexity. The components work synergistically within the solid matrix.
Solution Approach 2:
The patent uses excipients as intermediaries that facilitate the interaction between pH modifying agents and raltegravir. These excipients mediate the pH modification effects, enabling enhanced solubility and bioavailability while maintaining formulation stability and integrity. The excipients act as bridges between the active components and the dosage form matrix.
3Reliability
If acidifying agents are used to modulate microenvironmental pH, then solubility and stability improve, but potential harmful effects on gastrointestinal mucosa may increase
Solution Approach 1:
The patent creates local pH modification within the solid dosage form and at the drug dissolution interface, rather than creating system-wide acidification. The pH modifying agents are localized to the immediate microenvironment of raltegravir, enhancing solubility and stability only where needed. This local quality approach minimizes harmful effects on the broader gastrointestinal mucosa while achieving the desired drug performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition enhances solubility and stability, ensuring consistent drug release and improved bioavailability, matching the dissolution profile of reference drugs and reducing degradation products.
Implementation Method 1
the addition of pH modifying agents modulates physicochemical and pharmacokinetic properties of the formulation
Implementation Method 2
U.S. Application Publication No. 20080118559 discloses pharmaceutical formulations for oral administration in solid dosage forms that contain an alkali metal salt of raltegravir and an anti-nucleating agent
Data Source
AI summary
A solid pharmaceutical composition for oral administration comprising raltegravir or a pharmaceutical acceptable salt thereof, an acidifying agent selected from tartaric acid, citric acid, and fumaric acid, and one or more pharmaceutically acceptable excipients.